Replies to post #223748 on Biotech Values

[kris_kade]

It is, as often in bios PPS goes up once lack of funds as an overhang is removed especially for P3 assets companies.

Dan blamed the wider market for pitiful secondary pricing while big pharma is paying hand over fist on buyouts with huge premium.

Dan has B in my grade card.